Ivax Will Not Settle Lexapro Patent Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
Ivax denies speculation that it is in discussions with Forest to settle patent litigation regarding Forest's antidepressant Lexapro (escitalopram)
You may also be interested in...
Alphapharm To Market “Authorized” Generic Of Forest’s Lexapro
Deal allows Alphapharm to launch two weeks before the escitalopram patent expires in December 2009.
Alphapharm To Market “Authorized” Generic Of Forest’s Lexapro
Deal allows Alphapharm to launch two weeks before the escitalopram patent expires in December 2009.
Forest Pursuing Settlement With Alphapharm In Lexapro Patent Infringement Case
Forest stresses that negotiations do not affect ongoing litigation with Ivax and Cipla over the same patent.